Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 04 Aug 2022
Bulk billing ‘on verge of collapse’
5 August 2022 - Doctors have warned that the nation is facing the “collapse of bulk billing” in general practice, ...
Posted by Michael Wonder on 04 Aug 2022
ICER publishes evidence report on treatments for amyotrophic lateral sclerosis
4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds ...
Posted by Michael Wonder on 04 Aug 2022
U.S. prescription drug pricing doesn’t favour the patient: case of sub-optimal market for cancer pharmaceuticals
3 August 2022 - The high costs of cancer drugs impact patients negatively. In fact, the out of pocket cost ...
Posted by Michael Wonder on 04 Aug 2022
Panicked patients as popular medications get wiped from pharmacy shelves
4 August 2022 - Widely used medications — including one used to treat ADHD — are missing from Australian shelves amid ...
Posted by Michael Wonder on 04 Aug 2022
Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA mutated HER2 negative high-risk early breast cancer
4 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer ...
Posted by Michael Wonder on 04 Aug 2022
Travere Therapeutics provides regulatory updates on its development programs
3 August 2022 - Pegtibatinase granted breakthrough therapy designation by FDA. ...
Posted by Michael Wonder on 04 Aug 2022
TGA says go to BioMarin for Voxzogo
4 August 2022 - Vosoritide is a modified type C natriuretic peptide. ...
Posted by Michael Wonder on 04 Aug 2022
Pear Therapeutics and Cove Behavioral Health to provide patients access to prescription digital therapeutic for the treatment of opioid use disorder
3 August 2022 - Pear Therapeutics announced today that Cove Behavioral Health will provide access to Pear’s FDA authorised PDT reSET-O ...
Posted by Michael Wonder on 04 Aug 2022
There is an effective treatment for monkeypox, but it’s hard to get
29 July 2022 - A smallpox antiviral that’s effective against monkeypox is tied up in red tape, and gay health advocates ...
Posted by Michael Wonder on 04 Aug 2022
Economic evaluation of genomic/genetic tests: a review and future directions
1 August 2022 - It has been suggested that health economists need to improve their methods in order to meet the ...
Posted by Michael Wonder on 03 Aug 2022
AbbVie wins appeal in antitrust case over Humira 'patent thicket'
3 August 2022 - A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by ...
Posted by Michael Wonder on 03 Aug 2022
Seven years ago I ditched my private hospital cover. This is why I’m now getting it back.
4 August 2022 - Seven years ago I called my private health company and told them I was done. ...
Posted by Michael Wonder on 03 Aug 2022
Connecting electronic health records to clinical trials: how to embrace the promise of real world data
3 August 2022 - We all know that real world data from electronic health records could boost clinical trial efficiency ...
Posted by Michael Wonder on 03 Aug 2022
Bupa patients worried Ramsay Health Care hospital dispute will leave them out of pocket
3 August 2022 - A funding dispute between one of Australia's largest private hospital operators and a major insurer could ...
Posted by Michael Wonder on 03 Aug 2022
U.S. prescription drug market lacks certain competitive features: case of biosimilars
3 August 2022 - In a legal ruling reported yesterday, a 7th Circuit Court Federal Judge, Frank Easterbrook, affirmed dismissal of ...